Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Friedberg

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Current Hematologic Malignancy Reports|May 28, 2015
Treating Burkitt Lymphoma in AdultsCarla Casulo, Jonathan Friedberg
Best Practice & Research. Clinical Haematology|March 15, 2017
Transformation of marginal zone lymphoma (and association with other lymphomas)Carla Casulo, Jonathan Friedberg
Seminars in Hematology|March 31, 2010
Rituximab in indolent lymphomasTarek Sousou, Jonathan Friedberg
Expert Opinion on Emerging Drugs|June 25, 2014
Emerging protein kinase inhibitors for the treatment of non-Hodgkin's lymphomaSudy Jahangiri, Jonathan Friedberg, Paul Barr
Cancer Investigation|December 7, 2007
The role of bortezomib in the treatment of lymphomaPaul Barr, Richard Fisher, Jonathan Friedberg
Therapeutic Advances in Hematology|December 2, 2015
Recent advances in the development of Aurora kinases inhibitors in hematological malignanciesIqra Choudary, Paul M Barr, Jonathan Friedberg
Leukemia Research Reports|December 28, 2013
Hemophagocytic lymphohistiocytosis masquerading as progressive chronic lymphocytic leukemiaDeepak Kilari, Nicholas Venci, Jonathan Friedberg, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 12, 2020
Reply: Interim PET Assessment of Advanced Hodgkin Lymphoma: Is It Sufficient?Deborah M Stephens, Heiko Schoder, Hongli Li, et al.
Leukemia & Lymphoma|July 28, 2010
Management options, survivorship, and emerging treatment strategies for follicular and Hodgkin lymphomasMyron Czuczman, David Straus, John Gribben, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 24, 2004
Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide studyGary H Lyman, David C Dale, Jonathan Friedberg, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Current Hematologic Malignancy Reports|May 28, 2015
Treating Burkitt Lymphoma in AdultsCarla Casulo, Jonathan Friedberg
Best Practice & Research. Clinical Haematology|March 15, 2017
Transformation of marginal zone lymphoma (and association with other lymphomas)Carla Casulo, Jonathan Friedberg
Seminars in Hematology|March 31, 2010
Rituximab in indolent lymphomasTarek Sousou, Jonathan Friedberg
Expert Opinion on Emerging Drugs|June 25, 2014
Emerging protein kinase inhibitors for the treatment of non-Hodgkin's lymphomaSudy Jahangiri, Jonathan Friedberg, Paul Barr
Cancer Investigation|December 7, 2007
The role of bortezomib in the treatment of lymphomaPaul Barr, Richard Fisher, Jonathan Friedberg
Therapeutic Advances in Hematology|December 2, 2015
Recent advances in the development of Aurora kinases inhibitors in hematological malignanciesIqra Choudary, Paul M Barr, Jonathan Friedberg
Leukemia Research Reports|December 28, 2013
Hemophagocytic lymphohistiocytosis masquerading as progressive chronic lymphocytic leukemiaDeepak Kilari, Nicholas Venci, Jonathan Friedberg, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 12, 2020
Reply: Interim PET Assessment of Advanced Hodgkin Lymphoma: Is It Sufficient?Deborah M Stephens, Heiko Schoder, Hongli Li, et al.
Leukemia & Lymphoma|July 28, 2010
Management options, survivorship, and emerging treatment strategies for follicular and Hodgkin lymphomasMyron Czuczman, David Straus, John Gribben, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 24, 2004
Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide studyGary H Lyman, David C Dale, Jonathan Friedberg, et al.
Pageof 3